Search research articles
Contact Us
Filters
Showing results (81-90 of 144) with videos related to
Page
of 15
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
June 17, 2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer
Neil R Parikh, Eric M Chang, Nicholas G Nickols, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2020
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 16, 2026
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy
John Nikitas, Clayton P Smith, Wesley R Armstrong, et al.
Cell Reports
|
December 8, 2016
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome
Xian Liu, Tristan R Grogan, Haley Hieronymus, et al.
Cancer & Metabolism
|
September 28, 2018
CD38 is methylated in prostate cancer and regulates extracellular NAD<sup></sup>
Jack Mottahedeh, Michael C Haffner, Tristan R Grogan, et al.
JAMA Network Open
|
March 19, 2024
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems
Ananta Wadhwa, Charlotte Roscoe, Elizabeth A Duran, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 27, 2023
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials
John Nikitas, Wee Loon Ong, Nathalie Carrier, et al.
The Journal of Biological Chemistry
|
October 8, 2020
Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer
Mysore S Veena, Santanu Raychaudhuri, Saroj K Basak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 3, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
Wolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 144) with videos related to
Sort By:
Page
of 15
International Journal of Radiation Oncology, Biology, Physics
|
June 17, 2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer
Neil R Parikh, Eric M Chang, Nicholas G Nickols, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2020
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 16, 2026
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy
John Nikitas, Clayton P Smith, Wesley R Armstrong, et al.
Cell Reports
|
December 8, 2016
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome
Xian Liu, Tristan R Grogan, Haley Hieronymus, et al.
Cancer & Metabolism
|
September 28, 2018
CD38 is methylated in prostate cancer and regulates extracellular NAD<sup></sup>
Jack Mottahedeh, Michael C Haffner, Tristan R Grogan, et al.
JAMA Network Open
|
March 19, 2024
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems
Ananta Wadhwa, Charlotte Roscoe, Elizabeth A Duran, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 27, 2023
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials
John Nikitas, Wee Loon Ong, Nathalie Carrier, et al.
The Journal of Biological Chemistry
|
October 8, 2020
Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer
Mysore S Veena, Santanu Raychaudhuri, Saroj K Basak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 3, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
Wolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.
Page
of 15